Stay updated with breaking news from Protein Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Bio-Techne Co. (NASDAQ:TECH – Get Rating) have been assigned an average recommendation of “Buy” from the eight ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. […]
After years of failure, the Maryland company aims to attract the vaccine-hesitant with an alternative to mRNA shots. But will it find a market?
If it the FDA authorizes Novavax's COVID-19 vaccine, the Maryland-based company would target unvaccinated Americans and people who would benefit from boosters but have avoided the Pfizer-BioNTech and Moderna vaccines because of health concerns or conspiracy theories about their dangers.
Although the U.S. commitment eventually expanded to $1.8 billion, hardly any Novavax shots have found arms due to manufacturing issues, and most of the world has moved on.
Novavax hitched its wagon to the global coronavirus pandemic. Before most Americans truly grasped the scope of the danger, the small Maryland biotech startup had secured $1.6 billion in U.S. funding for its covid vaccine. Its moonshot goal: delivering 2 billion shots to the world by mid-2021.